Previous Next CORPORATE HIGHLIGHTS An innovative pharmaceutical company exclusively committed to advancing women’s health Worldwide commercial rights for multiple women’s health products Highly differentiated products for chronic conditions targeted to large and growing markets. Experienced management team with proven development and commercial success in women’s health U.S. commercial infrastructure in place with multiple distribution channels THERAPEUTICSMD UPDATE REGARDING COVID-19 Click here for more information © 2020 TherapeuticsMD, Inc. All Rights Reserved. Privacy Policy | Terms Of Use | Safe Harbor | Trademark Policy

Skip to main navigation Contact Us Email Alerts ABOUT US PRODUCTS MEDICAL AFFAIRS INVESTORS & MEDIA Investor Relations COVID-19 UPDATE Investors & Media Press Releases Events & Presentations Stock Information Financial History SEC Filings Financial Reports Financial Fundamentals Charters & Governance Analyst Coverage Contacts References and Links Logos and Media Resources Receive Email Alerts SEC Filings Annual Reports 2020 Annual Report 2019 Annual Report 2018 Annual Report SEC Filing Keyword Search Group Filing year - Any - Items per page 10 Filing date Form Description Filing Group View Nov 22, 2021 4 Statement of changes in beneficial ownership of securities 3,4,5 Nov 16, 2021 8-K/A Amendment to a previously filed 8-K Current Reports EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Nov 12, 2021 8-K Report of unscheduled material events or corporate event Current Reports EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Nov 12, 2021 10-Q Quarterly report which provides a continuing view of a company's financial position Quarterly Filings EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Oct 15, 2021 S-8 Securities offered to employees pursuant to employee benefit plans Registration Statements Oct 15, 2021 3 Initial filing by director officer or owner of more than ten percent. 3,4,5 Oct 15, 2021 4 Statement of changes in beneficial ownership of securities 3,4,5 Oct 01, 2021 4 Statement of changes in beneficial ownership of securities 3,4,5 Oct 01, 2021 8-K Report of unscheduled material events or corporate event Current Reports EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Oct 01, 2021 4 Statement of changes in beneficial ownership of securities 3,4,5 PAGINATION Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Displaying 1 - 10 of 970 results Data provided by Kaleidoscope. Shareholder Tools CORPORATE PRESENTATION Q3 2021 Earnings Presentation Nov 11, 2021 PRIMARY TXMD CONTACTS Investors Lisa M. Wilson In-Site Communications, Inc. 212-452-2793 ins_lwilson@therapeuticsmd.com lwilson@insitecony.com TherapeuticsMD 951 Yamato Road Suite 220 Boca Raton, FL 33431 561-961-1900 or ir@therapeuticsmd.com Media Kristen Landon Senior Vice President, Marketing TherapeuticsMD 951 Yamato Road Suite 220 Boca Raton, FL 33431 561-961-1900 or klandon@therapeuticsmd.com © 2021 TherapeuticsMD, Inc. All rights reserved. Privacy Policy Terms of Use Safe Harbor Trademark Policy